Results 21 to 30 of about 430 (135)

Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects#

Journal of Dermatological Treatment, 2022
Background Real-life efficacy data on the recently approved once daily application of chlormethine gel (CG) for mycosis fungoides (MF) is limited, and detailed characterization of the side effects and their management are strikingly sparse.
Shany Sherman, Iris Amitay-Laish, Omri Zidan, Emmilia Hodak, Hadas Prag Naveh, Yael A. Leshem, Elena Didkovsky, Yehonatan Noyman, Joseph Taieb   +8 more
core   +2 more sources

CHLORMETHINE (C) IN NEPHROSIS (N) [PDF]

Pediatric Research, 1980
C. was used in 18 Steroid-Resistant (SR) N and in 27 Steroid-Sensitive (SS)N. Two regimens were used: in the former a total dose of 0.8to1/mg/kg was given alone using 12 IV injections over one month. In the latter a total dose of 0.8 mg/kg was given over two periods of 4 days separated by one month, and was associated with Prednisone (2 mg/kg/day) and ...
G Lenoir, C Kleinknecht, P Guesry, M Broyer   +3 more
openaire   +2 more sources

Superalkali X3O (X = Li, Na, K) doped B12N12 nano-cages as a new drug delivery platform for chlormethine: A DFT approach

Computational and Theoretical Chemistry, 2022
In the present research, the interaction of chlormethine (CM) anticancer drug through its two sites (N and Cl) with the X3O-B12N12 nano-cages (X = Li, Na, K) was investigated using the DFT method at the B3LYP/6-31 g(d,p) level of theory in the gas phase ...
Siyamak Shahab, Masoome Sheikhi, Sadegh Kaviani, Kaviani, S., Shahab, S., Azarakhshi, F., Fatemeh Azarakhshi, Sheikhi, M.   +7 more
core   +2 more sources

Italian expert opinion on the treatment of mycosis fungoides with chlormethine gel: Results of a Delphi consensus

EJC Skin Cancer
Background: Mycosis fungoides (MF) is the most common form of a rare cutaneous T-cell lymphoma, often present with patches or plaques on the skin and characterized of malignant T cell infiltration.
Silvia Alberti Violetti, Marco Ardigò, Raffaele Filotico, Pietro Quaglino, Alessandro Pileri, Nicola Pimpinelli, Pierluigi Zinzani   +6 more
doaj   +3 more sources

Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series [PDF]

Acta Dermato-Venereologica
Cutaneous T-cell lymphomas are a heterogeneous group of non-Hodgkin lymphomas. Early stages are often controlled with skin-directed therapy, such as topical corticosteroids, topical chlormethine gel, or UV therapy, whereas advanced stages often warrant a
Signe Hedebo, Martin B. Pedersen, Lise M. Lindahl, Aska Drjlevic-Nielsen, Claus Johansen, Francesco d'Amore, Lars Iversen, Rikke Bech   +7 more
doaj   +2 more sources

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel

Cancer Management and Research, 2019
Daphné Denis,1 Nathalie Beneton,1 Kamel Laribi,2 Hervé Maillard1 1Dermatology Department, Centre Hospitalier Le Mans, Le Mans, France; 2Haematology Department, Centre Hospitalier Le Mans, Le Mans, France Abstract: Mycosis fungoides (MF) is ...
Denis D, Beneton N, Laribi K, Maillard H
doaj   +1 more source

Secondary Cutaneous Malignancies Associated with Topical Chlormethine in Cutaneous T-Cell Lymphoma: A Systematic Review

Journal of Cutaneous Medicine and Surgery
Topical chlormethine is well-established for use in cutaneous T-cell lymphomas (CTCL), such as mycosis fungoides (MF). Several studies have reported onset of secondary skin cancers resulting after use of chlormethine gel for CTCLs. This systematic review
Taghaddos, D (via Mendeley Data)
core   +2 more sources

Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides. [PDF]

Dermatol Ther (Heidelb), 2022
INTRODUCTION: Treatment of early-stage mycosis fungoides (MF) requires safe, skin-directed therapies. Medication side effects can lead to underutilization of effective therapies.
Alexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B.   +4 more
europepmc   +2 more sources

Clinical Validation of Imaging Biomarkers in Mycosis Fungoides. [PDF]

Exp Dermatol
ABSTRACT The composite index lesion severity (CAILS) score is used to monitor disease and therapeutic response in mycosis fungoides (MF), but is limited by interobserver variability and low sensitivity. Emerging imaging techniques, such as multispectral imaging (MSI), colourimetry and laser speckle contrast imaging (LSCI), offer objective alternatives ...
Wind SS, Beljaards ESM, Rijneveld R, Bruijnincx L, der Kolk TN, Jansen MAA, Yavuz Y, de Kam M, Burggraaf J, Klarenbeek N, Bosch J, Quint KD, Vermeer MH, Rissmann R, Next‐Generation ImmunoDermatology Consortium (NGID).   +14 more
europepmc   +2 more sources

Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing. [PDF]

Dermatol Ther (Heidelb), 2022
INTRODUCTION: The DNA-alkylating agent chlormethine (CL, or mechlorethamine) is approved in several countries worldwide as a 0.016% w/w topical CL gel formulation, to treat mycosis fungoides cutaneous T-cell lymphoma, with a positive benefit/risk ratio ...
Giuliano C, Frizzarin S, Alonzi A, Stimamiglio V, Ortiz-Romero PL.   +4 more
europepmc   +2 more sources